Which generation of targeted drugs does Ripotinib belong to? Clinical application analysis

Repotrectinib is classified as a new generation of targeted anti-cancer drugs and is a third-generation multi-target tyrosine kinase inhibitor (TKI). The drug was specially developed to solve the resistance mechanism of first- and second-generation TKIs, especially in the treatment of ROS1 fusion-positive non-small cell lung cancer (NSCLC) and NTRK fusion tumors, showing high selectivity and potent activity. Compared with early ROS1 inhibitors, repotinib has a stronger ability to penetrate the blood-brain barrier and can effectively deal with common drug-resistant mutations, such as G2032R, which makes it outstanding in the treatment of patients with advanced disease.

The structural design of Ripotinib is highly optimized, its small size allows it to deeply bind toATP binding site, effectively inhibiting the phosphorylation process of tyrosine kinase, thus blocking the signal transduction of cancer cells, thereby inhibiting tumor growth. This mechanism of action is not only effective for treatment-naïve patients, but also has potential therapeutic advantages for patients who have used other ROS1 or TRK inhibitors but developed resistance. According to foreign research trends, repotinib is also being explored for expanded indications in multiple solid tumor types, showing that it may have broad-spectrum anti-cancer properties.

Currently, Ripotinib has been approved by the FDA in the United States for the treatment of advanced lung cancer with specific gene mutations, marking a major development in the field of precision medicine. Clinically, doctors usually recommend this drug as a targeted treatment option after confirming that a patient has a ROS1 or NTRK fusion mutation. Because of its relatively precise indications, raptinib is usually not generally recommended as first-line treatment, but as a higher-level treatment when other TKI treatments fail or are intolerable. As more clinical studies advance, the drug is expected to become a new standard for the treatment of resistance mutations in ROS1 and NTRK, representing a further upgrade of targeted therapy from simple inhibition to dealing with drug-resistant mutations.

Reference materials:https://www.drugs.com/mtm/repotrectinib.html